Reduced Duodenal Cytochrome P450 3A Protein Expression and Catalytic Activity in Patients With Cirrhosis
Authors:
- MC ShuhartMSMC Shuhart
- 11 February 2009
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 85 (4) , 387-393
Abstract
The small intestine and liver express high levels of cytochrome P450 3A (CYP3A), an enzyme subfamily that contributes significantly to drug metabolism. In patients with cirrhosis, reduced metabolism ...Keywords
This publication has 36 references indexed in Scilit:
- THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Drug Metabolism and Disposition, 2006
- SERUM OSTEOPROTEGERIN AND RANKL LEVELS IN CHRONIC ALCOHOLIC LIVER DISEASEAlcohol and Alcoholism, 2006
- Intestinal and Hepatic CYP3A4 Catalyze Hydroxylation of 1α,25-Dihydroxyvitamin D3: Implications for Drug-Induced OsteomalaciaMolecular Pharmacology, 2006
- Induction of CYP3A4 by 1α,25-dyhydroxyvitamin D3 in HepG2 cellsLife Sciences, 2003
- Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shuntsHepatology, 2001
- Effects of Liver Disease on PharmacokineticsClinical Pharmacokinetics, 1999
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver DiseaseClinical Pharmacokinetics, 1995
- Human Alfentanil Metabolism by Cytochrome P450 3A3/4. An Explanation for the Interindividual Variability in Alfentanil Clearance?Anesthesia & Analgesia, 1993
- Pharmacokinetics of Midazolam Following Intravenous and Oral Administration in Patients with Chronic Liver Disease and in Healthy SubjectsThe Journal of Clinical Pharmacology, 1989
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973